Pembient Explained from Business to Conservation

Pembient is a company that's changing the game in the world of conservation and business. They're a biotech company that's developing a new way to preserve and store organs for transplantation.

Their technology uses a process called "suspension" to preserve organs, which allows them to be stored for extended periods of time without the need for refrigeration. This has huge implications for the field of organ transplantation.

One of the biggest challenges in organ transplantation is the shortage of available organs. According to the article, the US waiting list for organ transplants is over 100,000 people long. Pembient's technology has the potential to address this shortage by allowing organs to be preserved for longer periods of time.

Pembient's goal is to make organ transplantation more accessible and equitable, by reducing the need for refrigeration and increasing the availability of organs.

Pembient has raised a total of $100K in funding. This was achieved through a single funding round.

The funding round was a Seed round, which is typically an early stage of investment for startups. It took place on January 14, 2015.

IndieBio led the funding round, and it was the only investor involved.

Pembient is using 3D printing and genetic sequencing technology to fabricate lab versions of endangered animal parts.

George Bonaci, co-founder of Pembient, is making waves in the biotech field with his innovative approach. He recently partnered with nonprofit New Harvest and the Institute for Stem Cell and Regenerative Medicine (ISCRM) at the University of Washington to sequence the entire genome of the black rhinoceros.

Pembient's goal is to make cheaper parts and sell them to the market faster by creating lab versions of endangered animal parts. This could potentially help bring back extinct species like the Western black rhino, which is now officially extinct.

There are only a little more than 5,000 black rhinos left in the world, according to scientists. Pembient's crowd-funding campaign on Experiment.com aims to sequence the entire genome of the black rhinoceros, which could be a crucial step in reviving the species.

Legal entities associated with Pembient are listed below, ranked by their overall rank.

Pembient itself ranks 12th, with a total funding of $100K and a Tracxn score of 24/100.

Here's a breakdown of the top 3 companies associated with Pembient:

The funding amounts for these companies vary significantly, with Sutro Biopharma having the highest total funding at $175M.

Pembient's approach to conservation is a radical departure from traditional methods. They believe reducing demand for rhino horns is "infeasible" and "not really ethical" either.

Pembient's strategy involves developing and marketing synthetic rhino horns, which could potentially divert attention from efforts to end rhino poaching. More than 90% of "rhino horns" in circulation are already fake, mostly carved from buffalo horn or wood.

Conservationists have differing opinions on this approach. Some, like the International Rhino Foundation and Save The Rhino International, argue that developing synthetic horns takes away from efforts to end poaching, which is the "real problem."

TRAFFIC, a nonprofit that monitors the wildlife trade, is more open to the possibility of synthetic rhino horns playing a role in future conservation strategies.

A different take: Expeditors International